Purchases are not available yet. You can browse the site and sign in.
Psilocybin Half-Life: How Long a Microdose Lasts · Microdosing College
Science
Psilocybin Half-Life: How Long a Microdose Stays in Your System
By Microdosing College Editorial·Last updated October 30, 2026·7 min read
What does "psilocybin half-life" actually mean?
When people ask about the psilocybin half-life and how long it stays in your system, they are usually asking about two related but different things: how long the effects last, and how long the substance can be detected. This article focuses on the first question — because that is what matters most for practical dosing decisions — and draws on published pharmacokinetic data to explain the mechanics.
Psilocybin itself is not the pharmacologically active compound. After you swallow a truffle or capsule, intestinal alkaline phosphatases rapidly dephosphorylate psilocybin to psilocin (4-hydroxy-DMT), which crosses the blood-brain barrier and produces the effects you feel. The half-life that matters, therefore, is the elimination half-life of psilocin in plasma — not psilocybin itself, which clears even faster.
For a deeper look at how psilocybin is absorbed and broken down before it ever reaches psilocin, see our companion piece on psilocybin pharmacokinetics.
What the pharmacokinetic data show
The most cited controlled study on psilocin pharmacokinetics comes from Holze et al. (2023), published in Clinical Pharmacology & Therapeutics. In that double-blind, randomised crossover trial in healthy volunteers, the researchers measured plasma psilocin concentrations across several oral doses (5, 10, 25 and 30 mg of psilocybin).
Key findings from Holze et al. (2023):
Peak plasma concentration (Tmax): approximately 1.5–2 hours after oral ingestion across all doses tested.
Elimination half-life (t½): approximately 1.4–2 hours — meaning plasma levels fall by half every one-to-two hours after the peak.
Body weight: did not significantly alter pharmacokinetic parameters, which challenges the common assumption that heavier individuals need larger doses to feel the same effects.
A 2025 PRISMA systematic review of 14 pharmacokinetic studies, published in PMC, confirmed this picture: psilocin has a consistently short elimination half-life across trials, with most estimates falling in the 1–3 hour range depending on methodology and population (Pharmacokinetics of Psilocybin: A Systematic Review, PMC 2025).
By applying the half-life rule — plasma concentration halves roughly every 1.5 hours — you can estimate that after five half-lives (approximately 7–10 hours) less than 3 % of peak psilocin remains in plasma. In practice, the subjective effects of a standard clinical dose resolve well before that, as receptor occupancy and subjective experience do not track plasma concentration linearly throughout the elimination phase.
For the downstream fate of psilocin once it begins clearing — including the glucuronidation pathway that converts it to an inactive form excreted in urine — see psilocin glucuronidation and excretion explained.
What this means for a microdose specifically
A microdose sits well below the threshold used in clinical trials. Typical amounts — 0.5–2 g of fresh truffle, or roughly 0.1–0.3 g dried mushroom equivalent — deliver a fraction of the psilocybin used in research doses. The pharmacokinetic shape, however, remains the same: psilocin still peaks around 1.5–2 hours and still clears at a comparable rate.
What changes at lower doses is the magnitude, not the timing, of the plasma curve. That has two practical consequences:
1. Effects, if any, are time-limited. Even on a dosing day, a microdose is not pharmacologically active "all day." By mid-afternoon, psilocin plasma concentrations from a morning dose will be negligible. This matters because people sometimes attribute afternoon mood states — positive or negative — to the microdose when the compound is already largely cleared.
2. Timing the dose matters. Because the window of any pharmacological action is roughly the first 4–6 hours, dosing in the early morning (typically between 7:00 and 9:00 am) aligns the peak with working hours while allowing clearance before sleep. Evening dosing is generally discouraged not because of prolonged drug action but because even mild stimulant-adjacent effects during the peak window can delay sleep onset. For a full discussion of timing strategies, visit our protocols page.
To understand how long a microdose lasts in terms of reported subjective experience — which often diverges from pharmacokinetic predictions — see that dedicated guide.
Why effects can outlast plasma clearance
A common source of confusion is that many microdosers report subtle mood or cognitive shifts that persist beyond what plasma kinetics would predict. Several mechanisms may contribute:
Receptor desensitisation: 5-HT2A receptors can remain in a transiently altered functional state after psilocin has cleared, a downstream effect sometimes described as an "afterglow."
Second-messenger cascades: Serotonin receptor activation triggers intracellular signalling (including BDNF expression in animal models) that outlasts the receptor occupancy itself.
Expectation and attention: On a dosing day, people monitor themselves more closely. Subtle fluctuations in mood or cognition that would go unnoticed on a non-dosing day get attributed to the substance. This is one reason the self-blinding citizen-science study by Szigeti et al. (2021, eLife) found that microdose and placebo groups showed similar improvements — expectation powerfully shapes what people notice and report.
None of this means the effects are imaginary; it means the pharmacokinetic half-life is an incomplete account of the full experience. The acute pharmacology ends quickly; the psychological context around dosing does not.
Practical implications for dosing-day planning
Understanding the short psilocybin half-life reshapes how to think about a dosing day:
Morning is the natural window. A 7:00–9:00 am dose puts the pharmacological peak during the first half of a working day and allows near-complete clearance by early evening.
Avoid stacking doses. Because the tmax is only 1.5–2 hours, some people feel tempted to take a second dose if effects seem absent. This risks compounding doses into sub-threshold perceptual territory — and because tolerance to psilocin builds acutely within hours, a redose is unlikely to add meaningful effect while increasing unpredictability.
Sleep is not endangered by the drug itself (at typical microdose amounts), but any stimulant-adjacent quality during the early peak can interfere with falling asleep if dosed late in the day.
Use the protocol page at /protocols to match timing to your specific schedule and to review contraindications before starting.
If you are uncertain whether microdosing is appropriate for your health history or current medications, the screener is the right starting point before any decisions about timing or dosing.
Further reading in the Science pillar
This article is a cluster piece within the Microdosing Science pillar. Related articles that build on these pharmacokinetic foundations include:
Psilocybin 5-HT2A receptor occupancy (PET) — what brain imaging shows about how quickly psilocin engages serotonin receptors and how occupancy relates to subjective effects.
Psilocybin itself converts quickly to psilocin, which is the active compound. Psilocin has a plasma elimination half-life of approximately 1.4–2 hours, according to Holze et al. (2023, Clinical Pharmacology & Therapeutics). This means plasma levels halve roughly every one-to-two hours after peak concentration.
How long does a microdose of psilocybin stay in your system pharmacologically?+
Peak plasma psilocin is reached around 1.5–2 hours after ingestion. After five half-lives (approximately 7–10 hours) less than 3% of peak psilocin remains. Noticeable pharmacological effects from a microdose, if any, are typically resolved within 4–6 hours of dosing.
Does body weight change how long psilocybin lasts?+
Based on the data from Holze et al. (2023), body weight did not significantly alter psilocin pharmacokinetic parameters including half-life or time to peak. This suggests weight-based dose adjustments are not strongly supported by current pharmacokinetic evidence.
Why do some microdosers feel effects all day if the half-life is so short?+
Several factors can extend the perceived experience beyond plasma clearance: downstream receptor and signalling changes that outlast receptor occupancy, heightened self-monitoring on dosing days, and expectation effects. The Szigeti et al. (2021, eLife) self-blinding study found placebo and microdose groups showed similar improvements, highlighting how powerfully expectation shapes reported experience.
What time of day should I take a microdose given its short half-life?+
Most protocols recommend early morning (7:00–9:00 am) so that the pharmacological peak falls during working hours and the compound is largely cleared before sleep. Evening dosing is discouraged because even mild stimulant-adjacent effects during the 1–3 hour peak window can delay sleep onset. See our protocols page for full guidance.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
